Sulfated hyaluronic acid and esters thereof

Details Sulfated hyaluronic acid and esters thereof Sulfated hyaluronic acid and esters thereof

1996-02-08

2000-02-22

Fonda, Kathleen K.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

424493, 514 54, 514 56, 514 59, 536 187, 536 21, 536 53, 5361231, 536124, A61F 1300, A61K 31715

Patent

active

060277416

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention relates to the homogeneous sulfation of polysaccharides and semisynthetic derivatives thereof, in particular glycosaminoglycans such as hyaluronic acid and its esters and tetraalkylammonium salts, for the preparation of new biomaterials useful in biomedical, health care, and pharmaceutical applications, and to such biomaterials per se. Such sulfated derivatives exhibit anti-thrombotic activity as evidenced by the lengthening of both the thrombin time and the whole blood clotting time. Moreover, the absence of hemolysis and the growth and shape of endothelial cells placed in contact with such sulfated derivatives indicate that these materials are promising heparin-like compounds.
2. Description of Related Art
Many molecules of biological origin are polyelectrolytes, and their interactions are very important in a wide variety of biochemical reactions. Consequently, synthetic and/or semisynthetic polyelectrolytes have been in use for some time now. These polyelectrolytes mimic the biological characteristics of natural polyelectrolytes, and can have somewhat different characteristics compared to the starting material.
Polyelectrolytes of biological origin include sulfated polysaccharides, and in particular, heparin and its derivatives (D.A. Lane and U. Lindahl, Eds., Heparin Chemical and Biological Propertied, Clinical Applications, Edward Arnold, London), which play an important role in cell-substrate interactions, particularly in the process of viral activity inhibition, in the process of blood coagulation, in lipid removal, etc.
Heparin is the most biologically reactive member of the family of sulfated glycosaminoglycans. It is well known for its antithrombotic and anticoagulant properties. In fact, it is extensively used in the management of cardiovascular diseases and contributes enormously to the success of open heart surgery. Nevertheless, the structure of heparin is not simple and, due to the number of variations, is not entirely known. Commercial heparins consist of a spectrum of 21 heparins (Nader et al. (1974) Biochem. Biophys. Res. Commun. 57:488) ranging in molecular weights from 3,000 to 37,500 in varying anticoagulant activities.
The blood anticoagulant activity of heparin is attributed to structural features, e.g., degree of sulfation, degree of dissociation, particular sequences of COO.sup.-- and SO.sub.--.sub.3 groups, as well as to molecular shape and size. These factors appear to be related to biological activity by virtue of their importance in the ion binding capacity of heparin (Stivala et al. (1967) Arch. Biochem. Biophys. 122:40). By virtue of its highly negatively charged nature, heparin has a strong affinity for cations, and its activity is pH-dependent.
Most of the readily available natural polysaccharides have been sulfated in an attempt to obtain heparin analogues (Hoffman et al. (982) Carbohydrate Res. 2:115; Kindness et al. (1980) Brit. J. Pharmac. 69:675; Horton et al. (1973) Carbohydrate Res. 30:349; Okada et al. (1979) Makromol. Chem. 180:813; Kikuchi et al. (1979) Nippon Kagaku Kaishi 1:127; Manzac et al. (1981) Proc. Third M.I.S.A.O. 5:504), and recently, sulfate, carboxylic, and sulfonate groups were attached to synthetic polymers such as polystyrene (Kanmaugue et al. (1985) Biomaterials 6:297) and polyurethane (Ito et al.(1992) Biomaterials 13:131). The anticoagulant activities of these materials were much lower than that heparin, and were dependent on the type and binding of the substituents, the degree of substitution, and sequences.
Some chemical reactions are known which make it possible to sulfate polysaccharides (WO 88/00211; EP 0 340 628; Nagasawa et al. (1986) Carbohydrate Research 158:183-190), but it has not yet been possible to obtain sulfated polysaccharides which, besides the chemical and chemical-physical characteristics peculiar to such polysaccharides, also possess new characteristics, such as anticoagulant activity.


SUMMARY OF THE INVENTION

The present approach to studying the

REFERENCES:
patent: 2599172 (1952-06-01), Hadidian et al.
patent: 4141746 (1979-02-01), Schweiger
patent: 5013724 (1991-05-01), Petitou et al.
patent: 5202431 (1993-04-01), Della Valle et al.
patent: 5442053 (1995-08-01), della Valle et al.
Barbucci et al.--Journal of Materials Science: Material in Medicine, vol. 5 (1994) pp. 830-833.
OFOSU, Antithrombotic Mechanisms-pp. 432-449, in "Heparin", (1989).
Nagasawa et al.--Carbohydrate Research--vol. 158 (1986) pp. 183-190.
The Merck Index, Merck & Co., Inc., Whitehouse Station, NJ (1996) monograph 4793, pp. 813-814.
Ebert et al. "Medical Applications of Controlled Release, vol. II, Applications and Evaluations". Langer et al., eds. CRC Press, Inc., Boca Raton, Florida, 1984, Chapter 4, pp. 77-106.
WPIDS database record number 87-050330 for French patent 2,584,728 to Choay et al. issued Jan. 16, 1987, Derwent Information Ltd., 1987.
The Merck Index, Merck & Co., Inc. Rahway, NJ (1976) monograph 4510, pp. 607-608.
Karamanos et al. Int. J. Biochem. 1991, 23(1), 67-72.
Alessandri et al. Cancer Research 1993, 43, 1790-1797.

Affiliated with

Also associated with

Rating

Sulfated hyaluronic acid and esters thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfated hyaluronic acid and esters thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfated hyaluronic acid and esters thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-518292